Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

抗体细胞毒性中和 2019年冠状病毒病（COVID-19）队列医学免疫学病毒学药理学化学内科学体外生物化学传染病（医学专业）疾病

作者

Timothée Bruel,Lou-Léna Vrignaud,Françoise Porrot,Isabelle Staropoli,Delphine Planas,Florence Guivel‐Benhassine,Julien Puech,Matthieu Prot,Sandie Munier,William Bolland,Cathia Soulié,Karen Zafilaza,Clovis Lusivika‐Nzinga,Marie-Laure Meledge,Céline Dorival,Diana Molino,Hélène Péré,Youri Yordanov,Etienne Simon‐Lorière,David Veyer,Fabrice Carrat,Olivier Schwartz,Anne‐Geneviève Marcelin,Guillaume Martin‐Blondel,Magalie Garcia,Valentin Giraud,A Métais,F. Cazenave‐Roblot,Jean-Philippe Martellosio Anne-Marie Ronchetti,Thomas Gabas,Naima Hadjadj,Célia Salanoubat,Amélie Chabrol,P Housset,Agathe Pardon,Anne‐Laure Faucon,Valérie Caudwell,L Liblau,Laurent Alric,G. Pugnet,M. Mourguet,E. Bories,Delphine Bonnet,Sandrine Charpentier,Pierre Delobel,Alexa Debard,Cécile Beck,X. Boumaza,Stella Rousset Fanny Lanternier,Claire Delage,Elisabete Pires,Morgane Cheminant,N. Chauvin,Xavier Eyer Véronique Delcey Simon Bessis,Mélanie Cresta,Romain Gueneau Pélagie Thibaut,Marine Nadal,Martin Siguier,Marwa Bachir,Christia Palacios Valérie Pourcher,Cléa Melenotte,Antoine Fayçal,V. Bérot,Cécile Brin,Siham Djebara,Karen Zafilaza,Stéphane Marot,Sophie Sayon,Valentin Leducq,Isabelle Malet,Elisa Teyssou,Andréa Lacombe,Yasmine Abi Aad,Thibault Chiarabini,Raynald Feliho,Nadia Valin,Fabien Brigant,Julien Boize,Pierre-Clément Thiebaud,Marie Moreau,Cleudson Castro,Geoffroy Liégeon,Blandine Denis,Jean‐Michel Molina,Lucia Etheve André Cabié,Sylvie Abel,Ornella Cabras,K Guitteaud,Sandrine Pierre- François Vincent Dubee,Diama Ndiaye,Jonathan Pehlivan,Michael Phelippeau,Rafael Mahieu Alexandre Duvignaud,Thierry Pistone,A. Desclaux,Didier Néau,Catherine Faucher,Benjamin Festou,Magali Dupuy-Grasset,Véronique Loustaud‐Ratti,David Smadja,Christophe Choquet,Olivia Da Conceicao,Michael Thy,Lio Collas,C. Godard,Donia Bouzid,Vittiaroat Ing,Laurent Pereira,Thomas Pavlowsky,Camille RavautAntoine Asquier-Khati,David Boutoille,Marie Chauveau,Colin Deschanvres,F Bot,Marine Cailleaux,François Bénézit,Anne Maillard,Bernard Hue,Pierre Tattevin François Coustilleres,Claudia Carvalho-Schneider,Simon Jamard,Laëticia Petit,Krzysztof Mrózek,C. Theis,M. Vidal,Léo Sauvat,D. Lefevre,Guillaume Baronnet,Agnès Didier Florence Ader,Thomas Perpoint,Anne Conrad,Paul Chabert,Pilar Miralles Martín,Paul Loubet,Julien Mazet,Romaric Larcher,Daniel Frey,Amos Woerlen,Aline Remillon,Laure Absensur-Vuillaume,Pauline Bouquet Albert Trinh-Duc,Patrick Rispal Philippe Petua,Jacques Perrot,K. Delavigne,P. Cougoul,Jérémie Dion,Odile Rauzy Mathieu Blot,Thibault Sixt,Florian Moretto,Carole Charles,Lionel Piroth Sophie Circosta,L Léger,A. Arulananthan,Carine Lascoux,Pascaline Valérie,Leia Becam Yazdan Yazdanpanah,Ventzislava Petrov‐Sanchez,Alpha Diallo,Soizic Le Mestre,Guillaume Le Meut Isabelle Goderel,Frédéric Chau,Brahim Soltana,Jianming Tang,Jérémie Guedj,Yvanie Caillé

出处

期刊：Med [Elsevier]
日期：2023-10-01 卷期号：4 (10): 664-667

链接

nih.govdoi.org

标识

DOI：10.1016/j.medj.2023.07.007

摘要

Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.

求助该文献

最长约 10秒，即可获得该文献文件

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

今日热心研友